I had that same question. But is there a middle ground, where these companies wouldn’t enforce parents during a global emergency, but would expect to profit from the patents once the emergency is over? And that this expectation of delayed profits is a factor in their original decision to innovate?
I had that same question. But is there a middle ground, where these companies wouldn’t enforce parents during a global emergency, but would expect to profit from the patents once the emergency is over? And that this expectation of delayed profits is a factor in their original decision to innovate?
It’s always an emergency, lives are always at stake. That’s just the nature of the pharmaceutical business.